STOCK TITAN

Immunic Inc - IMUX STOCK NEWS

Welcome to our dedicated news page for Immunic (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunic's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.6%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-77.39%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
56.57%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.97%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.69%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.14%
Tags
earnings
Immunic Inc

Nasdaq:IMUX

IMUX Rankings

IMUX Stock Data

118.71M
49.38M
7.72%
58.07%
2.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Martinsried

About IMUX

immunic, inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, crohn's disease, and psoriasis. its lead development program is imu-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in phase 2 trial to treat crohn's disease. the company is also developing imu-935, an inverse agonist of rorgt; and imu-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. immu